S&P 500   4,998.76 (-0.25%)
DOW   37,959.42 (+0.49%)
QQQ   419.58 (-0.90%)
AAPL   165.44 (-0.96%)
MSFT   400.77 (-0.87%)
META   487.66 (-2.82%)
GOOGL   154.77 (-0.79%)
AMZN   176.19 (-1.69%)
TSLA   149.89 (-0.03%)
NVDA   819.22 (-3.25%)
AMD   151.03 (-2.61%)
NIO   3.88 (-3.00%)
BABA   68.75 (-0.19%)
T   16.38 (+0.31%)
F   12.13 (+0.58%)
MU   109.50 (-2.17%)
GE   151.20 (-1.14%)
CGC   7.76 (-0.89%)
DIS   112.11 (-0.28%)
AMC   3.22 (+10.27%)
PFE   25.59 (+0.79%)
PYPL   62.18 (+0.13%)
XOM   120.71 (+1.85%)
S&P 500   4,998.76 (-0.25%)
DOW   37,959.42 (+0.49%)
QQQ   419.58 (-0.90%)
AAPL   165.44 (-0.96%)
MSFT   400.77 (-0.87%)
META   487.66 (-2.82%)
GOOGL   154.77 (-0.79%)
AMZN   176.19 (-1.69%)
TSLA   149.89 (-0.03%)
NVDA   819.22 (-3.25%)
AMD   151.03 (-2.61%)
NIO   3.88 (-3.00%)
BABA   68.75 (-0.19%)
T   16.38 (+0.31%)
F   12.13 (+0.58%)
MU   109.50 (-2.17%)
GE   151.20 (-1.14%)
CGC   7.76 (-0.89%)
DIS   112.11 (-0.28%)
AMC   3.22 (+10.27%)
PFE   25.59 (+0.79%)
PYPL   62.18 (+0.13%)
XOM   120.71 (+1.85%)
S&P 500   4,998.76 (-0.25%)
DOW   37,959.42 (+0.49%)
QQQ   419.58 (-0.90%)
AAPL   165.44 (-0.96%)
MSFT   400.77 (-0.87%)
META   487.66 (-2.82%)
GOOGL   154.77 (-0.79%)
AMZN   176.19 (-1.69%)
TSLA   149.89 (-0.03%)
NVDA   819.22 (-3.25%)
AMD   151.03 (-2.61%)
NIO   3.88 (-3.00%)
BABA   68.75 (-0.19%)
T   16.38 (+0.31%)
F   12.13 (+0.58%)
MU   109.50 (-2.17%)
GE   151.20 (-1.14%)
CGC   7.76 (-0.89%)
DIS   112.11 (-0.28%)
AMC   3.22 (+10.27%)
PFE   25.59 (+0.79%)
PYPL   62.18 (+0.13%)
XOM   120.71 (+1.85%)
S&P 500   4,998.76 (-0.25%)
DOW   37,959.42 (+0.49%)
QQQ   419.58 (-0.90%)
AAPL   165.44 (-0.96%)
MSFT   400.77 (-0.87%)
META   487.66 (-2.82%)
GOOGL   154.77 (-0.79%)
AMZN   176.19 (-1.69%)
TSLA   149.89 (-0.03%)
NVDA   819.22 (-3.25%)
AMD   151.03 (-2.61%)
NIO   3.88 (-3.00%)
BABA   68.75 (-0.19%)
T   16.38 (+0.31%)
F   12.13 (+0.58%)
MU   109.50 (-2.17%)
GE   151.20 (-1.14%)
CGC   7.76 (-0.89%)
DIS   112.11 (-0.28%)
AMC   3.22 (+10.27%)
PFE   25.59 (+0.79%)
PYPL   62.18 (+0.13%)
XOM   120.71 (+1.85%)
Free Trial
NASDAQ:FMTX

Forma Therapeutics (FMTX) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)
Free FMTX Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$20.01
▼
$20.01
50-Day Range
$19.91
▼
$20.01
52-Week Range
$4.95
▼
$20.68
Volume
1 shs
Average Volume
847,595 shs
Market Capitalization
$957.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
FMTX stock logo

About Forma Therapeutics Stock (NASDAQ:FMTX)

Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.

FMTX Stock News Headlines

September 25, 2022 | finance.yahoo.com
Forma Therapeutics Holdings, Inc. (FMTX)
September 7, 2022 | finance.yahoo.com
Biotech Stock Roundup: GILD's Updates, FMTX Up on NVO Deal, SPRO Surges & More
April 19, 2024 | Paradigm Press (Ad)
AI “wealth window” is closing soon!
Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.
September 7, 2022 | apnews.com
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates GMTX, FMTX, SGFY, ECOM
September 7, 2022 | benzinga.com
The M&A Class Action Firm Announces the Investigation of Forma Therapeutics Holdings, Inc. - FMTX
September 2, 2022 | markets.businessinsider.com
4 Analysts Have This to Say About Forma Therapeutics Hldgs
September 2, 2022 | seekingalpha.com
Forma Therapeutics: Rare Disease Play
September 1, 2022 | markets.businessinsider.com
Novo Nordisk To Acquire Forma Therapeutics - Quick Facts
April 19, 2024 | Paradigm Press (Ad)
AI “wealth window” is closing soon!
Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.
September 1, 2022 | finance.yahoo.com
Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders
September 1, 2022 | marketwatch.com
Novo Nordisk to Buy Forma Therapeutics for $1.1 Billion >FMTX NVO
September 1, 2022 | apnews.com
FMTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Forma Therapeutics, Holdings Inc. Is Fair to Shareholders
September 1, 2022 | finance.yahoo.com
Forma Therapeutics to be acquired by Novo Nordisk in a cash deal valued at $1.1 billion
September 1, 2022 | finance.yahoo.com
UPDATE 1-Novo Nordisk to acquire Forma Therapeutics in $1.1. bln deal
August 11, 2022 | nasdaq.com
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) up 28%, but insiders miss out having sold stock earlier this year
August 3, 2022 | msn.com
Rigel Pharma Expands Blood Cancer Portfolio With Forma Therapeutics Licensing Pact
August 2, 2022 | finance.yahoo.com
Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia
July 29, 2022 | finance.yahoo.com
Forma Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 5, 2022
July 12, 2022 | finance.yahoo.com
Forma Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 8, 2022 | finance.yahoo.com
How Much Upside is Left in Forma Therapeutics Holdings, Inc. (FMTX)? Wall Street Analysts Think 379%
June 30, 2022 | finance.yahoo.com
Forma Therapeutics Announces Appointment of New Executive Team Members
June 22, 2022 | finance.yahoo.com
Can Forma Therapeutics Holdings, Inc. (FMTX) Climb 536% to Reach the Level Wall Street Analysts Expect?
June 15, 2022 | finance.yahoo.com
Bears are Losing Control Over Forma Therapeutics Holdings, Inc. (FMTX), Here's Why It's a 'Buy' Now
June 13, 2022 | finance.yahoo.com
Read Why Forma Therapeutics' Current Price Level Is 'Attractive Entry Point'
June 3, 2022 | finance.yahoo.com
Forma Therapeutics to Present at the Jefferies Healthcare Conference
May 26, 2022 | finance.yahoo.com
Forma Therapeutics Highlights Etavopivat Development Expansion and Introduces New Oncology Program from Research Pipeline at Inaugural Research and Development (R&D) Day
May 8, 2022 | finance.yahoo.com
Companies Like Forma Therapeutics Holdings (NASDAQ:FMTX) Are In A Position To Invest In Growth
See More Headlines
Receive FMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Forma Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
4/19/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:FMTX
CUSIP
N/A
CIK
1538927
Web
www.formatherapeutics.com
Phone
617-679-1970
Fax
N/A
Employees
166
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($4.00)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-172,960,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-39.68%
Return on Assets
-35.33%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.74
Quick Ratio
12.74

Sales & Book Value

Annual Sales
$100.56 million
Price / Sales
9.52
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$10.51 per share
Price / Book
1.90

Miscellaneous

Outstanding Shares
47,853,000
Free Float
45,082,000
Market Cap
$957.54 million
Optionable
Not Optionable
Beta
-0.94
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Frank D. LeeMr. Frank D. Lee (Age 54)
    Pres & CEO
    Comp: $963.2k
  • Mr. Todd E. ShegogMr. Todd E. Shegog (Age 56)
    Sr. VP & CFO
    Comp: $620.25k
  • Dr. John E. Bishop Ph.D. (Age 60)
    Sr. VP & Chief Technology Officer
  • Dr. David N. Cook Ph.D. (Age 64)
    Sr. VP & Chief Scientific Officer
  • Mr. Mario Vincent Corso C.F.A.
    Head of Investor Relations
  • Dr. Jeannette Potts J.D. (Age 60)
    Ph.D., Sr. VP, Gen. Counsel & Corp. Sec.
  • Ms. Xuandai Nguyen Ph.D.
    VP of Commercial Strategy & Marketing
  • Ms. Linea Aspesi (Age 52)
    Sr. VP & Chief HR Officer
  • Mr. Brian Lesser (Age 47)
    Sr. VP of Commercial
  • Dr. Ifeyinwa Osunkwo M.D.
    M.P.H., Sr. VP & Chief Patient Officer

Key Competitors

View All Competitors

FMTX Stock Analysis - Frequently Asked Questions

How were Forma Therapeutics' earnings last quarter?

Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) released its quarterly earnings results on Friday, November, 12th. The company reported ($0.91) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.96) by $0.05. During the same period in the previous year, the company earned ($0.67) earnings per share.

What other stocks do shareholders of Forma Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Forma Therapeutics investors own include Boeing (BA), Marvell Technology (MRVL), Trade Desk (TTD), Abbott Laboratories (ABT), CVS Health (CVS), Walt Disney (DIS), DocuSign (DOCU), Gilead Sciences (GILD), Intuit (INTU) and Neurocrine Biosciences (NBIX).

When did Forma Therapeutics IPO?

Forma Therapeutics (FMTX) raised $201 million in an initial public offering (IPO) on Friday, June 19th 2020. The company issued 11,800,000 shares at a price of $16.00-$18.00 per share. Jefferies' SVB Leerink and Credit Suisse served as the underwriters for the IPO.

This page (NASDAQ:FMTX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Your Money is Not Safe
American Alternative
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research